Phase IIa study of tosposertib, a dual TGFβRI and VEGFR2 inhibitor, in combination with pembrolizumab in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC). (ASCO 2026) - Apr 21, 2026 - Abstract #2635; Pres time: May 30, 2026; 01:30 PM - 04:30 PM; Location: Hall A - Posters and Exhibits; Poster Bd #: 425; P1/2 | "Funded by TiumBio Co., Ltd Clinical Trial Registration Number: NCT05784688 Background: Tosposertib (TU2218) is a highly potent dual inhibitor of the transforming growth factor-β type I receptor (TGFβRI/ALK5) and vascular endothelial growth factor receptor 2 (VEGFR2), designed to simultaneously target immunosuppressive tumor microenvironment signaling and angiogenesis. Tosposertib in combination with pembrolizumab demonstrated a manageable safety profile and encouraging antitumor activity in patients with R/M HNSCC, with particularly robust efficacy observed in the first-line setting and a favorable trend in PD-L1–high tumors. Best overall response by subgroups."
Combination therapy • Metastases • P2a data • Head and Neck Cancer • Mucositis • Oncology • Pruritus • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • KDR • PD-L1 • TGFB1 • TGFBR1
|
|
Hye Ryun Kim; Hun-taek Kim; Marya Chaney; Bhumsuk Keam; Sung-Bae Kim; Chang Gon Kim; Min Hee Hong; Jin Won Kim; Jin Hyoung Kang; Hojung An; Ji Hyun Park
|